ReviewBMC medicine2013
Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation.
Review in BMC medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interpreting whole genome sequencing for investigating tuberculosis transmission: a systematic review.BMC medicine · 2016Pooled it
- Clinical application of whole-genome sequencing in the management of extensively drug-resistant tuberculosis: a case report.Annals of clinical microbiology and antimicrobials · 2024Article
- Evaluation of Xpert MTB/RIF Ultra for the Diagnosis of Extrapulmonary Tuberculosis: A Retrospective Analysis in Saudi Arabia.Journal of epidemiology and global health · 2023Article
- Cerebrospinal fluid Gene XPERT (CBNAAT) in children with tuberculous meningitis.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- European Union training programme for tuberculosis laboratory experts: design, contribution and future direction.BMC health services research · 2020Article
- Deciphering Within-Host Microevolution ofMicrobiology and molecular biology reviews : MMBR · 2019Review
- Whole genome sequencing for drug resistance determination inAfrican journal of laboratory medicine · 2019Article
- Comparison of Quantamatrix Multiplexed Assay Platform and GenoType MTBDR Assay Using Smear-Positive Sputum Specimens From Patients With Multidrug- Resistant/Extensively Drug-Resistant Tuberculosis in South Korea.Frontiers in microbiology · 2019Article
- Article
- Time-and-motion tool for the assessment of working time in tuberculosis laboratories: a multicentre study.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018Article
- Rapid molecular assays for detection of tuberculosis.Pneumonia (Nathan Qld.) · 2018Review
- Molecular Diagnosis of Tuberculosis.Chonnam medical journal · 2018Review
- Severe Tuberculosis Requiring Intensive Care: A Descriptive Analysis.Critical care research and practice · 2017Article
- Nanostructured lipid carriers for incorporation of copper(II) complexes to be used againstDrug design, development and therapy · 2017Article
- Whole-genome sequencing illuminates the evolution and spread of multidrug-resistant tuberculosis in Southwest Nigeria.PloS one · 2017Article
- A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2016Article
- MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis.Journal of clinical microbiology · 2016Article
- The implications of whole-genome sequencing in the control of tuberculosis.Therapeutic advances in infectious disease · 2016Review
- Accurate Detection of Rifampicin-Resistant Mycobacterium Tuberculosis Strains.Sensors (Basel, Switzerland) · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this article, we give an overview of new technologies for the diagnosis of tuberculosis (TB) and drug resistance, consider their advantages over existing methodologies, broad issues of cost, cost-effectiveness and programmatic implementation, and their clinical as well as public health impact, focusing on the industrialized world. Molecular nucleic-acid amplification diagnostic systems have high specificity for TB diagnosis (and rifampicin resistance) but sensitivity for TB detection is more variable. Nevertheless, it is possible to diagnose TB and rifampicin resistance within a day and commercial automated systems make this possible with minimal training. Although studies are limited, these systems appear to be cost-effective. Most of these tools are of value clinically and for public health use. For example, whole genome sequencing of Mycobacterium tuberculosis offers a powerful new approach to the identification of drug resistance and to map transmission at a community and population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.